Sign In to Follow Application
View All Documents & Correspondence

Cationic Copolymers Formulated With Pigmented Cosmetic Compositions Exhibiting Radiance With Soft Focus

Abstract: A cosmetic composition is provided which includes a silicone elastomer, a cationic copolymer with monomeric units selected from at least an acryloylethyl tri(C1-C3 alkyl)ammonium salt and light reflecting platelet shaped particles. The compositions are particularly useful to impart radiance as well as soft focus effects onto the skin. A particularly useful cationic copolymer is acrylamide/acryloylethyl trimethylammonium chloride/tris(hydroxymethyl) acrylamidomethane copolymer.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
18 August 2010
Publication Number
47/2011
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2016-08-08
Renewal Date

Applicants

HINDUSTAN UNILEVER LIMITED
HINDUSTAN LEVER HOUSE, 165-166 BACKBAY RECLAMATION, MUMBAI, 400 020, INDIA

Inventors

1. POLONKA JACK
UNILEVER HOME & PERSONAL CARE USA, 40 MERRITT BOULEVARD, TRUMBULL, CONNECTICUT 06611, UNITED STATES OF AMERICA
2. BARTOLONE JOHN BRIAN
UNILEVER HOME & PERSONAL CARE USA, 40 MERRITT BOULEVARD, TRUMBULL, CONNECTICUT 06611, UNITED STATES OF AMERICA

Specification

FORM - 2 THE PATENTS ACT, 1970 (39 of 1970) & The Patents Rules, 2003 COMPLETE SPECIFICATION (See Section 10 and Rule 13) CATIONIC COPOLYMERS FORMULATED WITH PIGMENTED COSMETIC COMPOSITIONS EXHIBITING RADIANCE WITH SOFT FOCUS HINDUSTAN UNILEVER LIMITED, a company incorporated under the Indian Companies Act, 1913 and having its registered office at 165/166, Backbay Reclamation, Mumbai -400 020, Maharashtra, India The following specification particularly describes the invention and the manner in which it is to be performed CATIONIC COPOLYMERS FORMULATED WITH PIGMENTED COSMETIC COMPOSITIONS EXHIBITING RADIANCE WITH SOFT FOCUS The invention relates to compositions for improving the appearance of skin, particularly to provide good coverage over imperfections such as pores and uneven skin tone, while retaining a natural skin appearance. A matte effect is desired for users of color cosmetics. The matte finish overcomes the shiny effect engendered by greasy skin, particularly under hot and humid conditions. Absorbent fillers such as talc, silica, kaolin and other inorganic particulates have been used to achieve the effect by their optical properties. Imperfect skin can be hidden in two ways through manipulation of light transmission. In the first, components of the color cosmetic may simply reflect light back toward the source. An alternative approach is referred to as achieving a soft focus effect. Here the incoming light is distorted by scattering (lensing). Components of the color cosmetic in this mechanism operate as lenses to bend and twist light into a variety of directions. While it is desirable to hide imperfect skin through a matte effect, there is also a desire to achieve a healthy skin radiance. A cosmetic covering that is too opaque hides the skin under a paint-like coating. Imperfections are hidden but there is no radiance. Where light transmission is insufficiently hindered, the opposite occurs. Here the glow may be healthy but aesthetically displeasing skin topography and color may now be apparent. US 5 997 890 (Sine et al.), US 5 972 359 (Sine et al.), and US 6 174 533 B1 (SaNogueira, Jr.) are all directed to topical compositions to provide good coverage of skin imperfections. The solution proposed by these documents is the use of a metal oxide with a refractive index of at least about 2 and a neat primary particle size of from about 100 to about 300 nm. Preferred particulates are titanium dioxide, zirconium oxide and zinc oxide. Silicone gelling agents such as crosslinked organopolysiloxane elastomers because of their excellent skinfeei properties have been found useful in make-up compositions. For -2- instance, US 5 266 321 (Shukuzaki et al.) discloses an oily make-up composition comprised of a silicone gel crosslinked elastomer, titanium dioxide, mica and iron oxides. Japanese patent application 61-194009 (Harashima) describes a make-up composition comprising a cured organopolysiloxane elastomer powder and pigments which may be selected from talc, titanium dioxide, zinc oxide and iron oxides. WO 2005/070382 A2 discloses a pigmented cosmetic composition exhibiting radiance with soft focus. US 2007/0259803 A1 discloses that hydrophobically modified cationic polymers may be used to enhance deposition of particles. US 2004/0091444 Al discloses a decorative cosmetic and dermatological composition comprising at least one copolymer based on acryloyldimethyltaunine, the copolymer being suited as a thickener, bodying agent, emulsifier, film former, adhesive, lubricant, dispersant and/or stabilizer. WO 97/13497 A1 discloses a topical cosmetic composition comprising, amongst other things, a hydrophilic cationic resin, the composition exhibiting improved substantive properties. A challenge which has not been fully met by the known art is delivery of a composition with appropriate optics to achieve both soft focus and radiance properties in a system that still provides excellent skinfeel. SUMMARY OF THE INVENTION A cosmetic composition is provided which includes: (i) from 0.01 to 30% by weight of a crosslinked silicone elastomer; r\ the appended claims are by weight unless otherwise illustrated. EXAMPLES 1-8 Formulas suitable for the present invention are recorded in table I. EXAMPLES 9-22 Radiance in the form of a gloss measurement was evaluated on a Novogfoss® Gtossmeter. The Glossmeter geometry was first set with both detector and light source at 85° from normal. An appropriate reflection standard was used to calibrate the instrument Gloss (radiance) is reported as the percent difference in before and after treatment measurements. The larger the value (or less negative), the better the radiance effect. A haze determination was utilized to evaluate soft focus effects. For this purpose, a Hunter Lab Spectracolorimeter was employed. This instrument had an optical geometry of 0° incidence and 45° reflectance (both from normal). Reflectance measurements gauge the soft focus effect from an opaque surface. These measurements are reported as a Haze value. It is the difference between an initial (zero) reading and a final one after treatment Higher Haze values indicate a greater soft focus effect. Sample formula in 20 mg dosage was applied onto a human forearm, and let dry for 20 minutes. Treated forearms were then rinsed under water for 2 minutes, and let dry for another 20 minutes. Thereafter the treated areas were scanned on the Hunter Lab Spectracolorimeter and also on the Glossmeter. Before and after changes were recorded both for pre-rinse and post-rinse conditions to obtain the respective percent Gloss and Haze values. TABLE I Component Example (Weight %) 1 2 3 4 5 6 7 8 Cyclopentasiloxane 20.00 20.00 0.00 0.00 0.00 10.00 10.00 10.00 Cationic copolymer (7688 MP) 10.00 10.00 2.00 4.00 2.00 1.00 1.00 0.50 Ethylhexyl methoxycinnamate 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 Ethylhexyl salicylate 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 Polysorbate 40 1.62 1.62 1.62 1.62 1.62 1.62 1.62 1.62 Cetyl alcohol 1.55 1.55 1.55 1.55 1.55 1.55 1.55 1.55 Dimethicone 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Titanium dioxide coated 1.00 0.80 0.80 0.80 1.20 1.20 1.00 0.80 Polymethylmethacrylate beads (Ganzpearl® GMP 0820) 0.80 0.80 0.80 0.80 0.80 0.40 0.60 1.00 Glycerin monostearate 0.78 0.78 0.78 0.78 0.78 0.78 0.78 0.78 Mica (Timiron® MP111) 0.50 1.00 1.00 1.00 0.80 0.80 0.40 0.20 Silicone elastomer 3.50 3.50 0.50 0.50 0.50 1.50 1.50 1.50 Mica {Satin Mica) 0.50 0.50 0.50 0.50 1.00 0.50 0.50 1.00 Stearic acid 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 Cholesterol 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 Linoleic acid 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 Water Balance Balance Balance Balance Balance Balance Balance Balance TABLE II Example (Weight %) Component 9+ 10+ 11+ 12+ 13+ 14+ 15+ 16+ 17+ 18* 19+ 20+ 21 22+ Phase A Disodium EDTA I 0.10 I 0.10 0.10 0.10 [ 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 Glycerin 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Phase B Promulgen D® (Cetearyl alcohol & Ceteareth 20) 2.77 2.77 2.77 2.77 2.77 2.77 2.77 2.77 2.77 2.77 2.77 2.77 2.77 2.77 PEG-100 stearate 1.85 1.85 1.85 1.85 1.85 1.85 1.85 1.85 1.85 1.85 1.85 1.85 1.85 1.85 Ethylhexyl methoxycinnamate 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 Caprylic/capric triglycerides 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.75 Stearic acid 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 0.46 Cholesterol | 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 Phase C Titanium dioxide 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 Phase D Isohexadecane 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 Dimethicone 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 Phase G Simulgel INS® — 1.00 1.00 1.00 .. _ - — -- „ - 1.00 ,. ~ Cationic polymer 7688 MP ~ — — — 1.00 1.00 1.00 — ~ ~ — — 1.00 -- Merquat 5® -- - — — - " ~ 1.00 1.00 1.00 - -* ~ 1.00 Phase H Cyclopentasiloxane 8.50 8.50 8.50 8.50 8.50 8.50 8.50 8.50 8.50 8.50 8.50 8.50 8.50 8.50 Phase .1 DC 9045 Silicone Elastomer — 5.00 — ~ 5.00 ~ — 5.00 — — 5.00 5.00 5.00 5.00 Timiron MP111® — ~ 1.00 — ~ 1.00 ~ - 1.00 — 1.00 1.00 1.00 1.00 Ganzpearl GMP 820® (Polymethylmethacrylate) — — — — 1.00 — — 1.00 — — 1.00 1.00 1.00 1.00 Phase J DMDWi hydantoitvlodopropynyl butylcarbamate 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 Deionized water balance balance balance balance balance balance balance balance balance balance balance balance balance balance Optical Measurement \ i/alues After Application % Gloss Change* 8.7 1 -38.2 43.5 -10.3 -30.1 49.8 -8.3 -45.7 37.8 -12.3 5.1 11 17.2 8 Haze 6.3 136.4 8.1 12.7 37.8 9.2 13.7 36.3 8.2 12.6 71.3 71.2 73.7 70.1 Optical Measurement Values After Rinsing the Application % Gloss Change* -0.2 -1.4 1.1 -0.6 -30.1 47.6 -7.7 -19.1 29.8 -3.1 -1.6 -0.8 16.1 4.7 Haze 1.2 2 1.3 1.1 36.3 7.2 11.5 22.2 2.8 7.3 1.1 2.2 70.2 37.8 * Initial Gloss value of untreated forearm was 11.4 + Comparative examples -18- Example 9 is a control. A small effect on radiance/Gloss and soft focus/Haze was seen due to the presence of titanium dioxide. Examples 10,13 and 16 besides the base formula components (control) additionally included silicone elastomer and one each of the cationic copolymers. Identity of the copolymers are as follows. Merquat 5® is a trademark for acrylamide/methacryloyloxyethyl trimethyl ammonium methylsulfate copolymer; Simulgel INS® is a trademark for hydroxyethylacrylate/sodium acryloyldimethyltaurate copolymer; and Copolymer 7688 MP is a trademark for acrylamide/acryloylethyl trimethylammonium chloride/tris(hydroxymethyl)acrylamidomethane copolymer. All these formulas evidenced improvement in soft focus/Haze over the control. This benefit was particularly evident with example 13 (that utilizes 7688 MP) for both the pre-rinse and post-rinse Haze values. Nonetheless, radiance for all three formulas as measured by the Gloss change was poor relative to the control. Examples 11, 14 and 17 represent the base composition with cationic copolymer and light reflecting platelet-shaped (LRPS) particles, but absent any silicone elastomer. Example 14 (with 7688 MP) exhibited a significant radiance/Gloss benefit compared to the alternate copolymer formulas. Haze value also improved. Examples 12, 15 and 18 represent the base components with addition of cationic copolymer. Benefits in soft focus/Haze were evident but radiance/Gloss was inferior even to the control. Example 19 represents all components except the presence of cationic copolymer. Post-rinse gloss and haze value were no better than that of the control. Examples 20, 21 and 22 are fully formulated. These contain besides base components, a cationic polymer, silicone elastomer and LRPS particles. Example 21 with 7688 MP as the copolymer exhibited exceptional soft focus/haze both in pre- and post-rinse evaluations. Examples 20 and 22 also provided improvement in both benefits, but of a lesser magnitude than example 21. CLAIMS 1. A cosmetic composition comprising: (i) from 0.01 to 30% by weight of a crosslinked silicone elastomer; (ii) from 0.1 to 20% by weight of a cationic copolymer comprising monomer units of acryloylethyl tri(C1-C3 alkyl) ammonium salt; (iii) from 0.1 to 5% by weight of light reflecting platelet shaped particles; and (iv) a cosmetica I ly a ccepta bl e ca rri er, wherein the cationic copolymer is acrylamide/acryloylethyl trimethylammonium chloride/tris(hydroxymethyl)-acrylamidomethane copolymer. 2. The composition according to claim 1 wherein the light reflecting inorganic platelet shaped particles have a volume average particle size of 10,000 to 30,000 nm. 3. The composition according to claim 1 or claim 2 wherein the light reflecting inorganic platelet shaped particles are selected from titanium dioxide coated mica or bismuth oxychloride. 4. The composition according to any one of the preceding claims further comprising from 0.01 to 10% by weight of porous particles of polymethylmethacrylate. 5. The composition according to any one of the preceding claims further comprising from 0.05 to 2% by weight of a non-coated mica of volume average particle size ranging from 1,000 to 10,000 nm.

Documents

Application Documents

# Name Date
1 1753-MUMNP-2010-CORRESPONDENCE(IPO)-(28-12-2010).pdf 2010-12-28
1 1753-MUMNP-2010-RELEVANT DOCUMENTS [15-09-2022(online)].pdf 2022-09-15
2 1753-MUMNP-2010-FORM 3(10-12-2013).pdf 2013-12-10
2 1753-MUMNP-2010-RELEVANT DOCUMENTS [09-09-2021(online)].pdf 2021-09-09
3 1753-MUMNP-2010-FORM 3(10-11-2014).pdf 2014-11-10
3 1753-MUMNP-2010-ABSTRACT(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
4 1753-MUMNP-2010-FORM 3-(25-04-2015).pdf 2015-04-25
4 1753-mumnp-2010-assignment.pdf 2018-08-10
5 Petition Under Rule 137 [07-11-2015(online)].pdf 2015-11-07
5 1753-MUMNP-2010-CLAIMS(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
6 1753-MUMNP-2010-OTHER DOCUMENT(10-11-2015).pdf 2015-11-10
6 1753-mumnp-2010-claims.doc 2018-08-10
7 1753-MUMNP-2010-CORRESPONDENCE(10-11-2015).pdf 2015-11-10
7 1753-mumnp-2010-claims.pdf 2018-08-10
8 1753-MUMNP-2010-SPECIFICATION(AMENDED)(26-11-2015).pdf 2015-11-26
8 1753-MUMNP-2010-CORRESPONDENCE(29-1-2013).pdf 2018-08-10
9 1753-MUMNP-2010-CORRESPONDENCE(8-11-2011).pdf 2018-08-10
9 1753-MUMNP-2010-REPLY TO EXAMINATION REPORT(26-11-2015).pdf 2015-11-26
10 1753-MUMNP-2010-CORRESPONDENCE(IPO)-(8-8-2016).pdf 2018-08-10
10 1753-MUMNP-2010-OTHERS(26-11-2015).pdf 2015-11-26
11 1753-MUMNP-2010-CORRESPONDENCE(IPO)-(FER)-(3-12-2014).pdf 2018-08-10
11 1753-MUMNP-2010-MARKED COPY (26-11-2015).pdf 2015-11-26
12 1753-mumnp-2010-correspondence.pdf 2018-08-10
12 1753-MUMNP-2010-GENERAL POWER OF ATTORNEY (26-11-2015).pdf 2015-11-26
13 1753-MUMNP-2010-CORRESPONDENCEY(3-11-2010).pdf 2018-08-10
13 1753-MUMNP-2010-FORM 5 (26-11-2015).pdf 2015-11-26
14 1753-mumnp-2010-decription(complete).pdf 2018-08-10
14 1753-MUMNP-2010-FORM 3 (26-11-2015).pdf 2015-11-26
15 1753-MUMNP-2010-DESCRIPTION(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
15 1753-MUMNP-2010-FORM 2 (TITLE PAGE)(26-11-2015).pdf 2015-11-26
16 1753-MUMNP-2010-FORM 1(26-11-2015).pdf 2015-11-26
16 1753-mumnp-2010-form 1.pdf 2018-08-10
17 1753-MUMNP-2010-FORM 13(10-2-2012).pdf 2018-08-10
17 1753-MUMNP-2010-CLAIMS(26-11-2015).pdf 2015-11-26
18 1753-MUMNP-2010-ABSTRACT(26-11-2015).pdf 2015-11-26
18 1753-MUMNP-2010-FORM 18(8-11-2011).pdf 2018-08-10
19 1753-MUMNP-2010-FORM 2(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
19 1753-MUMNP-2010_EXAMREPORT.pdf 2018-08-10
20 1753-MUMNP-2010-FORM 2(TITLE PAGE)-(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
20 1753-mumnp-2010-wo international publication report a1.pdf 2018-08-10
21 1753-mumnp-2010-form 2(title page).pdf 2018-08-10
21 1753-MUMNP-2010-GENERAL POWER OF ATTORNEY(3-11-2010).pdf 2018-08-10
22 1753-mumnp-2010-form pct-isa-210.pdf 2018-08-10
23 1753-mumnp-2010-form 2.pdf 2018-08-10
23 1753-mumnp-2010-form pct-ipea-416.pdf 2018-08-10
24 1753-mumnp-2010-form pct-ipea-409.pdf 2018-08-10
24 1753-MUMNP-2010-FORM 3 (22-6-2013).pdf 2018-08-10
25 1753-mumnp-2010-form 5.pdf 2018-08-10
25 1753-MUMNP-2010-FORM 3(12-8-2011).pdf 2018-08-10
26 1753-MUMNP-2010-FORM 3(15-2-2011).pdf 2018-08-10
26 1753-mumnp-2010-form 3.pdf 2018-08-10
27 1753-MUMNP-2010-FORM 3(15-2-2012).pdf 2018-08-10
27 1753-MUMNP-2010-Form 3-190316.pdf 2018-08-10
28 1753-MUMNP-2010-FORM 3(22-5-2014).pdf 2018-08-10
28 1753-MUMNP-2010-Form 3-120816.pdf 2018-08-10
29 1753-MUMNP-2010-FORM 3(22-6-2013).pdf 2018-08-10
29 1753-MUMNP-2010-Form 3-081015.pdf 2018-08-10
30 1753-MUMNP-2010-FORM 3(23-1-2013).pdf 2018-08-10
30 1753-MUMNP-2010-FORM 3(8-8-2012).pdf 2018-08-10
31 1753-MUMNP-2010-FORM 3(23-1-2013).pdf 2018-08-10
31 1753-MUMNP-2010-FORM 3(8-8-2012).pdf 2018-08-10
32 1753-MUMNP-2010-FORM 3(22-6-2013).pdf 2018-08-10
32 1753-MUMNP-2010-Form 3-081015.pdf 2018-08-10
33 1753-MUMNP-2010-FORM 3(22-5-2014).pdf 2018-08-10
33 1753-MUMNP-2010-Form 3-120816.pdf 2018-08-10
34 1753-MUMNP-2010-FORM 3(15-2-2012).pdf 2018-08-10
34 1753-MUMNP-2010-Form 3-190316.pdf 2018-08-10
35 1753-MUMNP-2010-FORM 3(15-2-2011).pdf 2018-08-10
35 1753-mumnp-2010-form 3.pdf 2018-08-10
36 1753-mumnp-2010-form 5.pdf 2018-08-10
36 1753-MUMNP-2010-FORM 3(12-8-2011).pdf 2018-08-10
37 1753-MUMNP-2010-FORM 3 (22-6-2013).pdf 2018-08-10
37 1753-mumnp-2010-form pct-ipea-409.pdf 2018-08-10
38 1753-mumnp-2010-form 2.pdf 2018-08-10
38 1753-mumnp-2010-form pct-ipea-416.pdf 2018-08-10
39 1753-mumnp-2010-form pct-isa-210.pdf 2018-08-10
40 1753-mumnp-2010-form 2(title page).pdf 2018-08-10
40 1753-MUMNP-2010-GENERAL POWER OF ATTORNEY(3-11-2010).pdf 2018-08-10
41 1753-MUMNP-2010-FORM 2(TITLE PAGE)-(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
41 1753-mumnp-2010-wo international publication report a1.pdf 2018-08-10
42 1753-MUMNP-2010-FORM 2(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
42 1753-MUMNP-2010_EXAMREPORT.pdf 2018-08-10
43 1753-MUMNP-2010-ABSTRACT(26-11-2015).pdf 2015-11-26
43 1753-MUMNP-2010-FORM 18(8-11-2011).pdf 2018-08-10
44 1753-MUMNP-2010-CLAIMS(26-11-2015).pdf 2015-11-26
44 1753-MUMNP-2010-FORM 13(10-2-2012).pdf 2018-08-10
45 1753-MUMNP-2010-FORM 1(26-11-2015).pdf 2015-11-26
45 1753-mumnp-2010-form 1.pdf 2018-08-10
46 1753-MUMNP-2010-FORM 2 (TITLE PAGE)(26-11-2015).pdf 2015-11-26
46 1753-MUMNP-2010-DESCRIPTION(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
47 1753-MUMNP-2010-FORM 3 (26-11-2015).pdf 2015-11-26
47 1753-mumnp-2010-decription(complete).pdf 2018-08-10
48 1753-MUMNP-2010-CORRESPONDENCEY(3-11-2010).pdf 2018-08-10
48 1753-MUMNP-2010-FORM 5 (26-11-2015).pdf 2015-11-26
49 1753-mumnp-2010-correspondence.pdf 2018-08-10
49 1753-MUMNP-2010-GENERAL POWER OF ATTORNEY (26-11-2015).pdf 2015-11-26
50 1753-MUMNP-2010-CORRESPONDENCE(IPO)-(FER)-(3-12-2014).pdf 2018-08-10
50 1753-MUMNP-2010-MARKED COPY (26-11-2015).pdf 2015-11-26
51 1753-MUMNP-2010-CORRESPONDENCE(IPO)-(8-8-2016).pdf 2018-08-10
51 1753-MUMNP-2010-OTHERS(26-11-2015).pdf 2015-11-26
52 1753-MUMNP-2010-CORRESPONDENCE(8-11-2011).pdf 2018-08-10
52 1753-MUMNP-2010-REPLY TO EXAMINATION REPORT(26-11-2015).pdf 2015-11-26
53 1753-MUMNP-2010-CORRESPONDENCE(29-1-2013).pdf 2018-08-10
53 1753-MUMNP-2010-SPECIFICATION(AMENDED)(26-11-2015).pdf 2015-11-26
54 1753-mumnp-2010-claims.pdf 2018-08-10
54 1753-MUMNP-2010-CORRESPONDENCE(10-11-2015).pdf 2015-11-10
55 1753-MUMNP-2010-OTHER DOCUMENT(10-11-2015).pdf 2015-11-10
56 Petition Under Rule 137 [07-11-2015(online)].pdf 2015-11-07
56 1753-MUMNP-2010-CLAIMS(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
57 1753-MUMNP-2010-FORM 3-(25-04-2015).pdf 2015-04-25
57 1753-mumnp-2010-assignment.pdf 2018-08-10
58 1753-MUMNP-2010-FORM 3(10-11-2014).pdf 2014-11-10
58 1753-MUMNP-2010-ABSTRACT(GRANTED)-(COMPLETE)-(8-8-2016).pdf 2018-08-10
59 1753-MUMNP-2010-RELEVANT DOCUMENTS [09-09-2021(online)].pdf 2021-09-09
59 1753-MUMNP-2010-FORM 3(10-12-2013).pdf 2013-12-10
60 1753-MUMNP-2010-CORRESPONDENCE(IPO)-(28-12-2010).pdf 2010-12-28
60 1753-MUMNP-2010-RELEVANT DOCUMENTS [15-09-2022(online)].pdf 2022-09-15

ERegister / Renewals

3rd: 04 Nov 2016

From 29/01/2011 - To 29/01/2012

4th: 04 Nov 2016

From 29/01/2012 - To 29/01/2013

5th: 04 Nov 2016

From 29/01/2013 - To 29/01/2014

6th: 04 Nov 2016

From 29/01/2014 - To 29/01/2015

7th: 04 Nov 2016

From 29/01/2015 - To 29/01/2016

8th: 04 Nov 2016

From 29/01/2016 - To 29/01/2017

9th: 04 Nov 2016

From 29/01/2017 - To 29/01/2018

10th: 29 Dec 2017

From 29/01/2018 - To 29/01/2019

11th: 28 Dec 2018

From 29/01/2019 - To 29/01/2020

12th: 09 Dec 2019

From 29/01/2020 - To 29/01/2021